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Introduction {#ehf212054-sec-0001}
============

The human being has only 1--2% of its genome that codes for mRNAs building the basis for protein synthesis. In contrast, there are many more non‐coding RNAs (ncRNAs) in the genome, most of them with unknown function. Based on their size, ncRNAs are subdivided into (i) small ncRNAs (\<200 nucleotides long) including microRNAs (miRNA) and (ii) long ncRNAs (lncRNA), having a length between 0.2 and 2 Kb.[1](#ehf212054-bib-0001){ref-type="ref"} Virtually all cellular functions are being linked to ncRNAs and they have been identified to be important players in human pathology, including that of the cardiovascular system.

MicroRNAs as therapeutics and diagnostic markers in heart failure {#ehf212054-sec-0002}
=================================================================

About 1,500--2,000 human miRNAs have been identified that regulate at least half of all mRNAs.[2](#ehf212054-bib-0002){ref-type="ref"} As there are a number of reviews published on the mechanistic role of miRNAs and their potential use as therapeutic targets,[3](#ehf212054-bib-0003){ref-type="ref"}, [4](#ehf212054-bib-0004){ref-type="ref"}, [5](#ehf212054-bib-0005){ref-type="ref"}, [6](#ehf212054-bib-0006){ref-type="ref"}, [7](#ehf212054-bib-0007){ref-type="ref"} I here focus on some fundamental studies and novel aspects of miRNAs in heart failure. A pioneering work about a first miRNA to play a role in cardiac hypertrophy stems from the Olson laboratory, showing miR‐208 to be crucially involved in hypertrophic signalling.[8](#ehf212054-bib-0008){ref-type="ref"} Most miRNAs are more ubiquitously expressed and are not cell‐type specific. Thus, many miRNAs are expressed at relatively low levels under basal conditions but during pathological stress are strongly up‐regulated. An example is the neurologic‐enriched miRNA miR‐212/132 family, which becomes activated during heart failure (HF) in humans[9](#ehf212054-bib-0009){ref-type="ref"} and animal models.[10](#ehf212054-bib-0010){ref-type="ref"} These miRNAs have been shown to regulate cardiac hypertrophy in cardiomyocytes by targeting the anti‐hypertrophic transcription factor forkhead box O3 (FoxO3), leading to hyperactivation of the pro‐hypertrophic calcineurin/NFAT signalling pathway. Importantly, inhibition of miR‐132 rescued cardiac hypertrophy and HF in mice, suggesting a novel therapeutic approach for this pathology.[10](#ehf212054-bib-0010){ref-type="ref"} Another hallmark of adverse cardiac remodelling is cardiac fibrosis.[11](#ehf212054-bib-0011){ref-type="ref"} This is accompanied with increased secretion of extracellular matrix proteins and growth factors. An miRNA enriched in cardiac fibroblasts is miR‐21.[12](#ehf212054-bib-0012){ref-type="ref"} This miRNA is an endogenous brake for the ERK--MAP kinase inhibitor sprouty‐1, which is mechanistically involved in fibrosis development.[13](#ehf212054-bib-0013){ref-type="ref"} Both miR‐21 and miR‐29 have been shown to serve as potential therapeutic targets for cardiac fibrosis. Recently, circulating levels of miR‐29 were found to directly correlate with different forms of cardiac hypertrophy. [14](#ehf212054-bib-0014){ref-type="ref"} Thus, monitoring the level of this miRNA family may be useful for prognostic/therapeutic purposes in adverse cardiac remodelling disease entities. Next to cardiomyocytes and cardiac firbroblasts, the cardiac endothelium plays a major role in cardiac (patho)biology especially as recently suggested in Heart Failure with Preserved Ejection Fraction (HFpEF).[15](#ehf212054-bib-0015){ref-type="ref"} Our group recently identified an miRNA involved in the regulation of cardiac vascularization, that is, miR‐24.[16](#ehf212054-bib-0016){ref-type="ref"} This miRNA is highly expressed in cardiac endothelial cells. Blockade of endothelial miR‐24 limits myocardial infarction (MI) size in mice, via an increase of vascularity leading to improved cardiac function and survival. [16](#ehf212054-bib-0016){ref-type="ref"} In terms of diagnostics, a recent publication showed also the use of circulating miRNA patterns in distinguishing Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF). [17](#ehf212054-bib-0017){ref-type="ref"}

Long non‐coding RNAs emerging in heart failure research {#ehf212054-sec-0003}
=======================================================

Long non‐coding RNAs are defined as transcripts more than 200 nucleotides long that do not code for proteins.[18](#ehf212054-bib-0018){ref-type="ref"} Important to note is the fact that this definition may be preliminary as indeed some lncRNAs have been reported to encode short peptides in human tissues, which also may have functional effects.[19](#ehf212054-bib-0019){ref-type="ref"} A classification of lncRNAs can be viewed in the work of Thum and Condorelli. [1](#ehf212054-bib-0001){ref-type="ref"} Mechanistically, there are numerous ways how lncRNAs may function in the regulation of the genome. For instance, lncRNAs can interact with all macromolecules within the cell, including other RNA species, proteins, and DNA. Long non‐coding RNAs also have the ability for conformational switching, which can either activate or silence interaction with other molecules.[20](#ehf212054-bib-0020){ref-type="ref"} Long non‐coding RNAs can be found in the nucleus of a cell or in the cytoplasm or in both compartments. First, lncRNAs involved in cardiac development have been recently proposed---*Bvht* (Braveheart) and *Fendrr* (Foxf1 adjacent non‐coding developmental regulatory RNA).[21](#ehf212054-bib-0021){ref-type="ref"}, [22](#ehf212054-bib-0022){ref-type="ref"} *Bvht* seems to be a master gene required for cardiomyocyte differentiation. Unfortunately, *Bvht* seems to be specific to the mouse, making translations into humans difficult. The lncRNA *Fendrr* is higher conserved and regulates the expression of important cardiac transcription factors with knockout mice showing defects in cardiac development.[22](#ehf212054-bib-0022){ref-type="ref"} Only few studies have started to identify potential roles of lncRNAs in the pathogenesis of cardiac diseases. Deep sequencing studies revealed the profile of myocardial lncRNAs to be altered in HF in humans.[23](#ehf212054-bib-0023){ref-type="ref"} The lncRNA *Chrf* (cardiac hypertrophy‐related factor) was found to act as a sequence able to sequester miR‐489.[24](#ehf212054-bib-0024){ref-type="ref"} Interestingly, there are several lncRNAS associated to the locus of the cardiac‐specific gene myosin heavy chain 7 (*Myh7*); inhibition of the lncRNA *Mhrt* was mechanistically shown to induce cardiomyopathy subsequent to pressure overload, whereas restoring *Mhrt* protected the heart from HF.[25](#ehf212054-bib-0025){ref-type="ref"} Another lncRNA recently linked to cardiac pathology is *Carl* (cardiac apoptosis‐related lncRNA).[26](#ehf212054-bib-0026){ref-type="ref"} *Carl* binds miR‐539, an miRNA found to target the mRNA of a subunit of Prohibitin, where it seems to have a role in mitochondrial homeostasis. By this, *Carl* serves as an endogenous sponge regulating mitochondrial morphology and cell death in cardiomyocytes.

Non‐coding RNAs as diagnostics and cardiac cell cell communicators {#ehf212054-sec-0004}
==================================================================

Cells are usually able to produce different forms of vesicles including apoptotic bodies, microvesicles, and exosomes. This also is true for cardiovascular cells. These vesicles contain proteins, miRNA, mRNA, and lncRNAs (unpublished results). Exosomes, for example, are particularity enriched in small RNAs, such as miRNAs.[27](#ehf212054-bib-0027){ref-type="ref"} Of clinical interest, secreted exosomes can be isolated from biological fluids and their miRNA profile can be assessed, thus emerging as potential biomarkers for diseases.[28](#ehf212054-bib-0028){ref-type="ref"} This has been suggested also for extracellular longer RNAs, which can be detected in the plasma of patients with MI.[29](#ehf212054-bib-0029){ref-type="ref"} Recently, our group screened circulating miRNAs in no HF (no‐HF), HFrEF, and HFpEF patients using Taqman miRNA arrays (Life Technologies, Grand Island, NY, USA). A selected miRNA panel (miR‐30c, miR‐146a, miR‐221, miR‐328, and miR‐375) was further verified and validated in an independent cohort consisting of 225 patients. Indeed, this approach improved the discriminative value of BNP as an HF diagnostic. Combinations of two or more miRNA candidates with BNP had the ability to improve significantly predictive models to distinguish HFpEF from HFrEF compared with BNP alone (area under the receiver operating characteristic curve \>0.82).[17](#ehf212054-bib-0017){ref-type="ref"} Whether these miRNAs are also mechanistically important for HFpEF or HFrEF, disease pathologies are interesting and require further investigations. However, miRNA biomarkers may support diagnostic strategies in subpopulations of patients with HF. Locally, cells might also communicate with each other by shuttling non‐coding RNAs back and forth; for instance, cardiac fibroblasts can secrete exosomes that are enriched with miRNAs that could be taken up by recipient cardiomyocytes, provoking hypertrophy.[30](#ehf212054-bib-0030){ref-type="ref"} There is increasing evidence that cardiovascular cells are able to communicate via ncRNA transfer, and this also could lead into new strategies aiming at modulation of extracellular non‐coding RNA species.

Conclusion {#ehf212054-sec-0005}
==========

There has been a tremendous increase in knowledge about non‐coding RNAs in cardiovascular biology and disease within the last years. However, this represents only the tip of the iceberg that needs to be discovered to fully understand the importance of non‐coding RNAs. Likely, new non‐coding RNAs will help not only to understand better the mechanisms of heart failure but will develop into new concepts of theragnostic approaches. A variety of endeavours is currently undertaken by various groups worldwide to bring miRNA therapeutics into the clinics within the next 5--8 years. This includes target and drug candidate optimization, efficacy studies in small and large animals, toxicology and safety studies, and absorption, distribution, metabolism, and excretion studies leading to Phase I, Phase II, and Phase III studies until the market will be reached (*Figure* [1](#ehf212054-fig-0001){ref-type="fig"}).

![Clinical development plan for non‐coding RNA‐based therapeutics of which some are mentioned on the left. ADME; absorption, distribution, metabolism, excretion.](EHF2-2-108-g001){#ehf212054-fig-0001}
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